Perioperative Chemotherapy With FOLFOX Plus Cetuximab Versus Adjuvant FOLFOX Plus Cetuximab for Patients With Resectable Liver Metastases of Colorectal Carcinoma

Trial Profile

Perioperative Chemotherapy With FOLFOX Plus Cetuximab Versus Adjuvant FOLFOX Plus Cetuximab for Patients With Resectable Liver Metastases of Colorectal Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2015

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer; Liver metastases
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PANTER
  • Most Recent Events

    • 21 Sep 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 29 Apr 2015 Planned primary completion date changed from 1 Jan 2015 to 1 May 2015, as reported by ClinicalTrials.gov.
    • 29 Apr 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top